GlassScriptPhysician profile
Jennifer Cox
NPI 1669560827
$2,616.16
in general payments reported to CMS, 2019-2025
33 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $144 · 2021: $221 · 2022: $160 · 2023: $457 · 2024: $452 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $386.67 | 2019-2024 | |
| Novo Nordisk INC | $373.47 | 2020-2025 | Ozempic, Alhemo, Novoseven |
| Springworks Therapeutics, INC. | $182.60 | 2024-2025 | Ogsiveo, Gomekli |
| Servier Pharmaceuticals LLC | $163.99 | 2019-2021 | |
| Sobi, INC | $157.45 | 2025 | |
| Agios Pharmaceuticals, INC. | $145.92 | 2023 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $124.40 | 2022 | |
| Incyte Corporation | $124.03 | 2025 | Niktimvo |
| Merck Sharp & Dohme LLC | $119.47 | 2024-2025 | Prevymis |
| Pfizer INC. | $94.63 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $79.77 | 2023 | |
| Alexion Pharmaceuticals, INC. | $79.28 | 2023-2024 | Koselugo |
| Rare Disease Therapeutics, INC. | $67.13 | 2024-2025 | Xromi, Purixan |
| Global Blood Therapeutics, INC. | $61.87 | 2020-2021 | |
| Csl Behring | $58.64 | 2024 | Idelvion, Hemgenix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $48.15 | 2021-2022 | |
| Y-Mabs Therapeutics, INC. | $44.40 | 2023-2024 | Danyelza |
| Bayer Healthcare Pharmaceuticals INC. | $42.11 | 2025 | |
| Adaptive Biotechnologies Corporation | $35.37 | 2024 | Clonoseq |
| Teleflex LLC | $25.75 | 2025 | Arrow |
| Syndax Pharmaceuticals, INC. | $23.92 | 2025 | |
| Hema Biologics, LLC | $23.48 | 2024 | Sevenfact |
| Mesoblast, INC. | $23.30 | 2025 | Ryoncil |
| Celgene Corporation | $21.39 | 2025 | Breyanzi |
| Emmaus Medical, INC. | $20.59 | 2025 | Endari |
| Janssen Biotech, INC. | $20.57 | 2025 | Tecvayli |
| Uswm, LLC | $18.80 | 2024 | Iwilfin |
| Abbott Laboratories | $16.98 | 2025 | Navitor |
| Takeda Pharmaceuticals U.S.A., INC. | $16.82 | 2020 | |
| Karyopharm Therapeutics INC. | $15.21 | 2025 | Xpovio |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.